Abstract
Oxiracetam was labeled with 99mTc using sodium dithionite (Na2S2O4) as a reducing agent. The influence exerted on the labeling yield by the amounts of the reducing agent and substrate, pH, temperature, and reaction time was studied to optimize the labeling process. Biodistribution studies show that the 99mTcoxiracetam complex is suitable as a highly selective tracer for brain imaging.
Similar content being viewed by others
References
Sanad, M.H., J. Anal. Sci. Technol., 2014, vol. 5, p. 23.
Mettler, F.A. and Guiberteau, M.J., Essentials of Nuclear Medicine Imaging, Philadelphia: Saunders, 2006, ch. 1, pp. 1–13.
Neirinckx, R.D., Canning, L.R., Piper, I.M., et al., J. Nucl. Med., 1987, vol. 28, pp. 191–202.
Walovitch, R.C., Hill, T.C., Garrity, S.T., et al., J. Nucl. Med., 1989, vol. 30, pp. 1892–1901.
Bruno, J. and Nicolaus, R., Drug Develop. Res., 1982, vol. 2, no. 5, pp. 463–474.
Andrei, G.M. and Sadie, M.R., Drugs, 2010, vol. 70, no. 3, pp. 287–312.
Maina, G., Fiori, L., Torta, R., et al., Neuropsychobiology, 1989, vol. 21, pp. 141–145.
Stensbol, T.B., Madsen, U., and Krogsgaard-Larsen, P., Curr. Pharm. Des., 2002, vol. 8, no. 10, pp. 857–872.
Sanad, M.H. and Alhussein, A.I., Radiochim. Acta, 2017, doi.org/10.1515/ract-2017-2804.
Sanad, M.H. and Talaat, H.M., Radiochemistry, 2017, vol. 59, no. 4, pp. 396–401.
Sanad, M.H., Radiochemistry, 2013, vol. 55, no. 5, pp. 539–544.
Sanad, M.H., Marzook, E.A., and El-Kawy, O.A., Radiochemistry, 2017, vol. 59, no. 6, pp. 624–629.
Mathew, S.G., Eur. J. Biochem., 1978, vol. 17, no. 2, pp. 535–547.
Ferreira, D.D., Boratto, F.A., Cardoso, V.N., et al., J. Label. Compd. Radiopharm., 2015, vol. 56, no. 14, pp. 689–695.
Sanad, M.H., Sallam, Kh.M., Marzook, F.A., and Abd-Elhaliem, S.M., J. Label. Compd. Radiopharm., 2016, vol. 59, pp. 484–491.
Sanad, M.H. and Borai, E., Radiochim. Acta, 2015, vol. 103, pp. 879–891.
Sanad, M.H., Talaat, H.M., and Ahmed, S.M.F., Radiochim. Acta, 2017, doi.org/10.1515/ract-2017-2840.
Chen, X., Guo, Y., Zhang, Q., et al., J. Organomet. Chem., 2008, vol. 693, pp. 1822–1828.
Zhuang, Z.P., Kung, M.P., Hou, C., et al., Nucl. Med. Biol., 2005, vol. 32, pp. 171–184.
Siddiqui, N., Husain, A., Chaudhry, L., et al., J. Appl. Pharm. Sci., 2011, vol. 1, no. 4, pp. 12–19.
Ramalingaiah, H., Jagadeesh, R.V., and Puttaswamy, M., J. Mol. Catal. A: Chemical, 2007, vol. 265, nos. 1–2, p. 70.
Ferreira, D.D., Boratto, F.A., Cardoso, V.N., et al., Int. J. Nanomed., 2015, vol. 10, pp. 2441–2450.
Geskovski, N., Kuzmanovska, S., Crcarevska, M.S., et al., J. Label. Compd. Radiopharm., 2013, vol. 56, no. 14, pp. 689–695.
Kowalsky, R.J. and Falen, S.W., Radiopharmaceuticals in Nuclear Pharmacy and Nuclear Medicine, Washington: Am. Pharmacists Association, 2011, 3rd ed.
Zhang, J., Wang, X., and Jin, C., J. Radioanal. Nucl. Chem., 2007, vol. 272, no. 1, pp. 91–94.
Viveksarathi, K. and Kannan, K., Int. J. Pharm. Investig., 2015, vol. 5, pp. 87–91.
Satpati, B.K., Mukherjee, A., Banerjee, S.K., and Venkatesh, M., Appl. Radiat. Isot., 2006, vol. 64, no. 8, pp. 888–892.
Erfani, M., Hassanzadeh, L., Ebrahimi, S.E.S., and Shafiei, M., Iran J. Nucl. Med., 2012, vol. 20, no. 1, pp. 25–31.
Jun, B.Z., Xue, B.W., and Chun, J.T., J. Radioanal. Nucl. Chem., 2004, vol. 262, no. 2, pp. 505–507.
Jun, B.Z., Xue, B.W., and Chun, J.T., J. Radioanal. Nucl. Chem., 2007, vol. 273, no. 1, pp. 15–17.
Jun, B.Z., Gang, L., and Xue, B.W., J. Radioanal. Nucl. Chem., 2009, vol. 279, no. 3, pp. 783–785.
Author information
Authors and Affiliations
Corresponding author
Additional information
Published in Russian in Radiokhimiya, 2018, Vol. 60, No. 1, pp. 55–59.
The text was submitted by the authors in English.
Rights and permissions
About this article
Cite this article
Sanad, M.H., Sallam, K.M. & Salama, D.H. 99mTc-Oxiracetam as a Potential Agent for Diagnostic Imaging of Brain: Labeling, Characterization, and Biological Evaluation. Radiochemistry 60, 58–63 (2018). https://doi.org/10.1134/S1066362218010101
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1134/S1066362218010101